BioLineRx (BLRX) Cash from Operations (2013 - 2025)

BioLineRx's Cash from Operations history runs 13 years deep, the most recent figure standing at 3200000.0 for Q4 2025.

• On a quarterly basis, Cash from Operations rose 62.83% year-over-year to 3200000.0 in Q4 2025; TTM through Dec 2025 was 8074000.0, a 81.6% increase from a year earlier, with the FY2025 full-year figure at 8074000.0, up 81.6% from the prior year.
• Cash from Operations retreated to 3200000.0 in Q4 2025 per BLRX's latest filing, from 2106000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 4991000.0 in Q4 2023 and bottomed at 14109000.0 in Q1 2024.
• The 5-year median for Cash from Operations is 6259000.0 (2021), against an average of 6218400.0.
• Across the five-year window, Cash from Operations surged 187.82% in 2023 and tumbled 272.51% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 5503000.0 in 2021, then retreated by 3.27% to 5683000.0 in 2022, then jumped by 187.82% to 4991000.0 in 2023, then tumbled by 272.51% to 8610000.0 in 2024, then jumped by 62.83% to 3200000.0 in 2025.
• Per Business Quant, the three latest BLRX Cash from Operations figures stand at 3200000.0 (Q4 2025), 2106000.0 (Q3 2025), and 177000.0 (Q2 2025).